Idioma:

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Goyal, Gaurav ; Heaney, Mark L. ; Collin, Matthew ; Cohen-Aubart, Fleur ; Vaglio, Augusto ; Durham, Benjamin H. ; Hershkovitz-Rokah, Oshrat ; Girschikofsky, Michael ; Jacobsen, Eric D. ; Toyama, Kazuhiro ; Goodman, Aaron M. ; Hendrie, Paul ; Cao, Xin-xin ; Estrada-Veras, Juvianee I. ; Shpilberg, Ofer ; Abdo, André ; Kurokawa, Mineo ; Dagna, Lorenzo ; McClain, Kenneth L. ; Mazor, Roei D. ; Picarsic, Jennifer ; Janku, Filip ; Go, Ronald S. ; Haroche, Julien ; Diamond, Eli L.

Blood, 2020-05, Vol.135 (22), p.1929-1945 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Autor: Goyal, Gaurav ; Heaney, Mark L. ; Collin, Matthew ; Cohen-Aubart, Fleur ; Vaglio, Augusto ; Durham, Benjamin H. ; Hershkovitz-Rokah, Oshrat ; Girschikofsky, Michael ; Jacobsen, Eric D. ; Toyama, Kazuhiro ; Goodman, Aaron M. ; Hendrie, Paul ; Cao, Xin-xin ; Estrada-Veras, Juvianee I. ; Shpilberg, Ofer ; Abdo, André ; Kurokawa, Mineo ; Dagna, Lorenzo ; McClain, Kenneth L. ; Mazor, Roei D. ; Picarsic, Jennifer ; Janku, Filip ; Go, Ronald S. ; Haroche, Julien ; Diamond, Eli L.
Assuntos: Clinical Trials as Topic ; Erdheim-Chester Disease - diagnosis ; Erdheim-Chester Disease - genetics ; Erdheim-Chester Disease - therapy ; Female ; Histiocytosis, Langerhans-Cell - diagnosis ; Histiocytosis, Langerhans-Cell - genetics ; Histiocytosis, Langerhans-Cell - therapy ; Humans ; Male ; MAP Kinase Signaling System - drug effects ; MAP Kinase Signaling System - genetics ; Molecular Targeted Therapy ; Mutation ; Prognosis ; Proto-Oncogene Proteins B-raf - antagonists & inhibitors ; Proto-Oncogene Proteins B-raf - genetics
É parte de: Blood, 2020-05, Vol.135 (22), p.1929-1945
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600–mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 2 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

United States: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.